Psychiatric Disorders
An introduction to touchPSYCHIATRY
Neuropsychiatric conditions (e.g. autism, ADHD, bipolar disorder, depression, schizophrenia), are leading causes of disability worldwide and constitute a substantial health burden. Advances in diagnosis, treatment and prevention of mental health conditions have included enhanced understanding of their genetic basis and the identification of modifiable risk factors. Emerging novel pharmacological strategies include ketamine, medical cannabis and guanfacine. Technologies such as deep-brain stimulation and transcranial magnetic stimulation are proving beneficial in a number of disorders. However, further understanding of the molecular processes involved in the pathogenesis of psychiatric disorders is needed.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
In our inaugural touchNEUROLOGY Future Leaders 2025 campaign, we celebrate the next generation of neurologists, rising stars shaping the future of clinical practice, research, and education across neurological specialties.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
As touchNEUROLOGY approaches 20 years of providing education for busy neurologists, we are looking to the future—and it certainly looks bright!
"Continued support for research, and for the patients themselves, is absolutely critical. I’m grateful for the opportunity to help bring some of this work to light." Dr Anissa Abi-Dargham is Chair of Psychiatry and Behavioral Health at the Renaissance ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
“Your brain thrives on connection; meeting people, interacting and sharing ideas is vital for not only your individual brain health but also our species survival” - Dr Hannah Critchlow Nominated as a touchNEUROLOGY Future Leader 2025, we speak with Dr ...
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Nominated as a touchNEUROLOGY Future Leader 2025, and in collaboration with International Forum on Mood and Anxiety Disorders (IFMAD) 2025 rising star award, Dr Laure shares the key experiences, mentors and emerging treatment strategies that shape her evolving career. Her contributions to the Group for the Study of Resistant Depression (GSRD), combined with award-winning clinical work, mark her as one to watch in the field of psychiatry and psychotherapy.
Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital is an emerging leader in psychiatry. His work combines rigorous clinical training with a research-driven focus on depression, encompassing meta-analyses, register-based studies and clinical trials. From early clinical exposure in primary care to a PhD in psychopharmacology, Dr Lisinski’s path reflects a commitment to scientific inquiry, innovation in treatment, and patient-centred care.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
From 4–6 June 2025, the 20th International Forum on Mood and Anxiety Disorders (IFMAD) will take place in Budapest, Hungary, marking a significant milestone for this long-standing event in psychiatric research and practice. Since its inception in 1999, IFMAD has brought together global experts to explore the latest advances in the understanding and treatment of mood and anxiety disorders.
In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.
Article highlights Multiple screening tests are available to screen patients for cognitive impairment, and the Confusion Assessment Method is a helpful test to screen for delirium in the immediate postoperative period. Medicine reconciliation and identification and removal of potentially inappropriate ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
